BR112021023209A2 - Terapia com vacina anti-abeta - Google Patents
Terapia com vacina anti-abetaInfo
- Publication number
- BR112021023209A2 BR112021023209A2 BR112021023209A BR112021023209A BR112021023209A2 BR 112021023209 A2 BR112021023209 A2 BR 112021023209A2 BR 112021023209 A BR112021023209 A BR 112021023209A BR 112021023209 A BR112021023209 A BR 112021023209A BR 112021023209 A2 BR112021023209 A2 BR 112021023209A2
- Authority
- BR
- Brazil
- Prior art keywords
- administered
- vaccine therapy
- mpla
- amyloid
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810 | 2019-05-21 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 | ||
| PCT/EP2020/064172 WO2020234405A1 (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021023209A2 true BR112021023209A2 (pt) | 2022-01-18 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021023209A BR112021023209A2 (pt) | 2019-05-21 | 2020-05-20 | Terapia com vacina anti-abeta |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI916375B (zh) * | 2020-06-25 | 2026-03-01 | 英商梅迪繆思有限公司 | 軸突損傷之預防 |
| WO2024156912A1 (en) * | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Anti-abeta vaccine therapy |
| WO2025109524A1 (en) * | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| CA2633399C (en) * | 2005-12-12 | 2016-01-26 | Ac Immune S.A. | Therapeutic vaccine |
| MX2011009654A (es) * | 2009-03-18 | 2011-10-12 | Ac Immune Sa | Metodo para uso terapeutico. |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| EP2632434B1 (en) | 2010-10-26 | 2025-08-20 | AC Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| CA2811188C (en) * | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| MA52180A (fr) * | 2018-04-10 | 2021-02-17 | Ac Immune Sa | Vaccins thérapeutiques anti-abêta |
-
2020
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en not_active Ceased
- 2020-05-20 MY MYPI2021006840A patent/MY210394A/en unknown
- 2020-05-20 JP JP2021569155A patent/JP7701734B2/ja active Active
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 IL IL288252A patent/IL288252B1/en unknown
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko active Pending
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/en active Pending
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL288252A (en) | 2022-01-01 |
| JP2022533422A (ja) | 2022-07-22 |
| MY210394A (en) | 2025-09-18 |
| KR20220010552A (ko) | 2022-01-25 |
| CN113853214A (zh) | 2021-12-28 |
| CA3138145A1 (en) | 2020-11-26 |
| SG11202112329RA (en) | 2021-12-30 |
| JP7701734B2 (ja) | 2025-07-02 |
| IL288252B1 (en) | 2026-06-01 |
| TW202110425A (zh) | 2021-03-16 |
| US20220226447A1 (en) | 2022-07-21 |
| WO2020234405A1 (en) | 2020-11-26 |
| MX2021014102A (es) | 2022-02-11 |
| EP3972633A1 (en) | 2022-03-30 |
| CL2021003051A1 (es) | 2022-07-22 |
| AU2020277682A1 (en) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luo et al. | The dual role of lipids of the lipoproteins in Trumenba, a self-adjuvanting vaccine against meningococcal meningitis B disease | |
| NZ701881A (en) | Vaccines for hsv-2 | |
| CL2021003051A1 (es) | Terapia de vacuna anti-abeta. | |
| BR9509190A (pt) | Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano | |
| BR112020016454A8 (pt) | Tratamento utilizando rna que codifica citocina | |
| Lang et al. | Aging adults and seasonal influenza: does the vitamin d status (h) arm the body? | |
| BRPI0610093A2 (pt) | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente | |
| BRPI0920791B8 (pt) | Uso de peptídeo na preparação de medicamento para tratar câncer e kit | |
| CA2943334A1 (en) | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof | |
| ES2262460T1 (es) | Prevencion y tratamiento de enfermedad amiloidogenica. | |
| BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
| BR0108924A (pt) | Composição umonogênica adaptada para administração a um hospedeiro humano para o tratamento ou prevenção da aterosclerose, vacina, e, método de tratamento ou profilaxia da aterosclerose | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| BR112021021213A2 (pt) | Administração heteróloga de vacinas de tau | |
| CN103533953A (zh) | 针对肺炎链球菌的疫苗 | |
| JP2017511327A5 (cg-RX-API-DMAC7.html) | ||
| JP2021521149A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0619747B8 (pt) | método para produzir uma composição de vacina terapêutica, construto antigênico, composição de vacina, usos de um construto antigênico, e, método para preparar e produzir um medicamento para o tratamento de uma condição ou doença associada com amilóide | |
| JP2017511327A (ja) | 免疫応答を誘導するための新規方法 | |
| JP2015529677A5 (cg-RX-API-DMAC7.html) | ||
| BR112021022087A2 (pt) | Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus | |
| US20230285531A1 (en) | Toll-like receptor 2 agonists and vaccines and uses thereof | |
| ES2547855T3 (es) | Procedimiento de desencadenamiento o inducción de una respuesta inmunitaria | |
| CO2025016879A2 (es) | Composiciones para el uso en el tratamiento del acné | |
| BR112022021797A2 (pt) | Proteínas de fusão para imunoterapia contra o câncer e doenças infecciosas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |